An interventional study of Radiotherapy in Prostate Cancer, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Prostatic Neoplasms with a site in Belgium — 42 open to participants now, 77 under way, 33 of them phase 3. Prostatic Neoplasms · Belgium.
Among the 236 studies in Prostatic Neoplasms with a site in Belgium, this one is the 120th largest by planned enrollment of the 206 interventional ones that give a count, is one of 9 that started in 2026, is one of 31 with no phase, reaches primary completion later than 59 of the 76 other live ones, and was the 228th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →42 of the 236 studies in Prostatic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Australia and 21 more countries
Ages 18+ · Men only
BioNTech SE · Sites in Belgium, United States, Australia and 7 more countries
Ages 18+ · Men only
Jules Bordet Institute · Sites in Belgium
Men only
Bayer · Sites in Belgium, Finland, France and 13 more countries
Ages 18+ · Men only
Amgen · Sites in Belgium, United States, Australia and 15 more countries
Ages 18+ · Men only
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 59 · Phase 3 102 · Phase 4 6
First in 1992; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 188 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 283 across the 206 interventional studies, 805 across the 27 observational. Of the 152 that completed or were terminated, 78 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 236 have an industry lead sponsor. The 10 most frequent:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 350 studies on the registry; 64 are open to participants now.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Prostatic Neoplasms with a site in Belgium that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT05352178Phase 3Universitaire Ziekenhuizen KU LeuvenMetastasis-directed Therapy for Oligorecurrent Prostate Cancer | 2027-04-25 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 236 studies in Prostatic Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective clinical study compares patient-reported outcome measures (PROMs) after adaptive or conventional radiotherapy in prostate cancer. Adaptive radiotherapy (ART) aims to reduce uncertainties related to daily anatomical variations, thereby improving treatment accuracy while decreasing gastrointestinal (GI) and genitourinary (GU) toxicity. This study, conducted at Cliniques universitaires Saint-Luc (Brussels and Ottignies sites), analyzes and compares toxicities in patients treated with ART on Ethos and those treated with conventional radiotherapy on Halcyon.
The primary objective of the study is to demonstrate that ART reduces gastrointestinal, urinary, and general side effects induced by radiotherapy. Additionally, the secondary objectives include assessing the duration of these effects, correlating them with dosimetric data, analyzing the management of toxicities through the Noona e-health application, as well as evaluating the use of this application by both patients and healthcare providers.
The study includes men aged 18 years or older with prostate cancer undergoing curative-intent treatment, with an ECOG performance status of 0 to 1, and able to use the Noona application. Patients with a history of rectal or bladder treatment, or those who have already received pelvic radiotherapy, are excluded. Two groups are compared: patients treated with conventional radiotherapy on Halcyon (Ottignies site) and those treated with adaptive radiotherapy on Ethos (Brussels site).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment planned and delivered on the Halcyon machine with non-adaptive conventional radiotherapy.
Radiation: Radiotherapy
Treatment planned and delivered on the Ethos machine with adaptive radiotherapy.
Radiation: Radiotherapy
Prostate cancer patients will be treated radiotherapy.
Demonstration that adaptive radiotherapy in prostate cancer helps reduce radiotherapy-induced side effects (digestive, urinary, and general toxicity) using PROMS questionnaires.
In this clinical study, we aim to demonstrate that adaptive radiotherapy (ART) in prostate cancer can reduce radiotherapy-induced side effects (digestive, urinary, and general toxicity). Daily adaptation of treatment plans not only ensures better target coverage but also accounts for daily variations in the position or deformation of organs at risk (OARs). Consequently, ART could reduce the occurrence of genitourinary (GU) and gastrointestinal (GI) side effects, either early (during or shortly after treatment) or at later stages (up to one year after completion of treatment). Three questionnaires will be used: the Expanded Prostate Cancer Index Composite-26 (EPIC-26), the EuroQol 5 Dimensions (EQ-5D) and the International Prostate Symptom Score (IPSS).
Time frame: 3 years
Evaluation of the time to recovery from treatment-related adverse effects using PROMS questionnaires.
This study will collect PROMs and clinical data to assess whether the duration of adverse effects before recovery differs between the two radiotherapy approaches (adaptive versus conventional).
Time frame: 3 years
Correlation of the duration of adverse effects collected with PROMS questionnaire with the dosimetric data.
The duration of adverse effects before recovery may also be correlated with dosimetric analyses. Indeed, ART could allow better dose coverage of the target volumes while reducing the dose delivered to the OARs. The Ethos system enables monitoring of the accumulated dose to both targets and OARs, thereby allowing complementary dosimetric analyses.
Time frame: 3 years
Evaluation of the management of treatment-related toxicity using the e-health application using a PREM questionnaire at the end of the study.
Since patients will complete PROMs questionnaires through an e-health application, this will allow a qualitative analysis of the application. Specific questions will be asked to patients regarding their use of the application.
Time frame: 3 years
Number of participants and medical staff satisfied by the ease of use of an e-health application during radiotherapy using a questionnaire.
This study could thus highlight a novel approach to managing patient toxicity and assess whether it could improve overall treatment management.
Time frame: 3 years
Started Jan 2026 (actual). Primary completion is estimated for Mar 2029, 38 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 38 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain →